Friday 6 November 2026 Export HCM’s income statement to Excel — free account

HUTCHMED (China) Limited Sponsored ADR

HCM Healthcare Drug Manufacturers Specialty & Generic

HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.

14.27 0.35 +2.51%

Follow HCM

Alert me

Market cap: $2.5B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: 3.53
Beneish M: −1.20
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.46%

Capital & Financial Ratios $m

Size

Market Cap 2,480.00

Revenue ttm 10,127.80

Net income ttm 967.70

Free cash flow ttm (171.77)

Net debt Q (1,280.31)

Valuation

P/E 0.00

Forward P/E —

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 5.64

Debt / equity Q 0.07

Interest coverage Q —

Growth

Revenue growth Q +510.07%

Operating income growth Q —

EPS, this year −86.21%

EPS, next year A +28.59%

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A +33.83%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

EV/FCF against its own 10 years 73.42%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	886	836	1,367	1,375
Receivables	132	172	149	138
Inventory	50	50	41	41
Other	28	8	10	—
	1,097	1,067	1,567	1,553

	2023	2024	2025	Q'26
Payables	36	43	46	34
ST’ Debt	31	23	25	22
Other	—	—	—	4
	403	377	316	275

Compound Annual Growth %

	10y	5y	3y
Sales	11.90%	19.20%	8.76%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	28.46%	19.25%	25.25%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	2.62
’24	—	—	—	—	0.22
’23	—	—	—	—	0.58
’22	—	—	—	—	(2.13)
’21	—	—	—	—	(1.23)
’20	—	—	—	—	(0.90)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	549
’24	—	—	—	—	630
’23	—	—	—	—	838
’22	—	—	—	—	426
’21	—	—	—	—	356
’20	—	—	—	—	228

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	12	—	—	—
’25	—	(73)	—	(65)	(65)
’24	—	(40)	—	0	0
’23	—	—	—	—	219
’22	—	—	—	—	(269)
’21	—	—	—	—	(204)
’20	—	—	—	—	(62)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	7	—	—	—
’25	—	(82)	—	(79)	(89)
’24	—	(50)	—	(17)	(17)
’23	—	(24)	—	(33)	187
’22	—	(16)	—	(37)	(305)
’21	(255)	(9)	—	(17)	(221)
’20	(8)	(4)	—	(20)	(82)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	216	241	214	205	228	356	426	838	630	549	10,128		+10.9%	—	—	—	—
	Gross margin, %	27.65	27.11	32.77	21.84	17.31	27.49	27.04	54.12	44.64	38.68	44.40		+11.0 pt	Powerpack HUTCHMED (China) Limited Sponsored ADR’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(47)	(54)	(87)	(141)	(190)	(216)	(410)	58	(1)	499	(3,348)		n/m
	EBT margin, %	(21.92)	(22.20)	(40.47)	(68.87)	(83.23)	(60.58)	(96.25)	6.96	(0.18)	90.92	(33.06)		+112.8 pt
	Net income	15	(23)	(71)	(104)	(116)	(167)	(360)	101	38	458	968		+46.7%
Per share, $
Per share, $	Revenue	1.81	1.95	1.61	1.54	1.63	2.25	2.52	4.93	3.68	3.20	0.00		+6.5%
	Earnings	0.10	(0.22)	(0.57)	(0.80)	(0.90)	(1.23)	(2.13)	0.59	0.22	2.66	(2.94)		+44.0%
	Cash flow	(0.08)	(0.07)	(0.25)	(0.61)	(0.44)	(1.29)	(1.59)	1.29	0.00	(0.38)	0.00		+18.8%
	Capex	(0.04)	(0.04)	(0.05)	(0.06)	(0.14)	(0.11)	(0.22)	(0.19)	(0.10)	(0.14)	0.00		+16.3%
	Free cash flow	(0.12)	(0.11)	(0.30)	(0.67)	(0.58)	(1.39)	(1.80)	1.10	(0.10)	(0.52)	0.00		+18.0%
	Book value	1.71	3.93	3.10	2.35	3.72	6.56	3.76	4.37	4.51	7.29	0.00		+17.5%
	Shares, m	119	123	133	133	140	159	169	170	171	172	—		+4.1%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	EV/Sales	0.00	0.00	(0.11)	(0.06)	(0.15)	(0.19)	(0.10)	(0.08)	(0.07)	(0.13)	(0.13)		(0.1)
	EV/FCF	2.98	81.97	4.71	1.19	2.63	0.96	0.81	36.37	4.30	5.58	7.45		14.1
Cash, $m
Cash, $m	Operating cash flow	(10)	(9)	(33)	(81)	(62)	(204)	(269)	219	0	(65)	(125)		+23.7%
	Capex	(4)	(5)	(6)	(9)	(20)	(17)	(37)	(33)	(18)	(24)	(47)		+21.0%
	Free cash flow	(14)	(14)	(39)	(89)	(82)	(221)	(305)	187	(17)	(89)	(172)		+22.9%
Balance, $m
Balance, $m	Working capital	72	328	285	204	372	900	486	694	690	1,252	1,278		+37.3%
	Net debt	(57)	(322)	(270)	(154)	(374)	(601)	(578)	(807)	(753)	(1,274)	(1,280)		+41.3%
	Shareholders’ equity	204	485	412	313	519	1,040	637	743	772	1,251	1,275		+22.3%
Returns, %
Returns, %	ROA	4.09	(5.69)	(13.24)	(21.26)	(21.14)	(18.57)	(30.04)	8.73	2.95	30.19	0.00		+26.1 pt
	ROIC	(19.83)	(20.43)	(40.81)	(57.40)	(84.84)	(46.78)	(432.48)	0.00	(147.26)	0.00	0.00		+19.8 pt
	ROE	7.64	(7.76)	(16.67)	(29.24)	(30.23)	(24.98)	(43.05)	14.60	4.98	45.17	0.00		+37.5 pt
People
People	Employees	563	590	714	853	1,280	1,759	2,025	1,988	1,811	1,796	—		+13.8%
	Revenue/emp, $m	0.38	0.41	0.30	0.24	0.18	0.20	0.21	0.42	0.35	0.31	—		(2.5%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RGC Regencell Bioscience Holdings Limited	$2.6B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.5B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%
XERS Xeris Biopharma Holdings, Inc.	$2.4B	— (loss-making)	— (loss-making)	+44.16% (above 0%: growing)	+1,478.95% (above 0%: growing)	+93.18% (above 0%: growing)	88.41%	15.78%	Compare
PRGO Perrigo Company plc	$2.2B	— (loss-making)	— (loss-making)	−5.24% (below 0%: shrinking)	n/m	+138.48% (above 0%: growing)	32.45%	2.34%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.1B	13.7×	11.7×	+22.69% (above 0%: growing)	−38.37% (below 0%: shrinking)	−38.18% (below 0%: shrinking)	51.30%	24.00%	Compare
TRLV Trulieve Cannabis Corp.	$2.1B	— (loss-making)	— (loss-making)	−20.12% (below 0%: shrinking)	n/m	+24.49% (above 0%: growing)	64.30%	0.00%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.0B	— (loss-making)	— (loss-making)	+13.11% (above 0%: growing)	+150.00% (above 0%: growing)	−18.69% (below 0%: shrinking)	99.13%	29.58%	Compare
ALVO Alvotech	$1.8B	— (loss-making)	111×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.6B	13.3×	14.3×	+27.64% (above 0%: growing)	+29.41% (above 0%: growing)	+85.49% (above 0%: growing)	61.64%	18.01%	Compare
Median of peers	$2.1B	—	14.3×	+22.69%	+29.41%	+40.82%	59.05%	15.78%

All 84 Drug Manufacturers Specialty & Generic stocks →

HUTCHMED (China) Limited Sponsored ADR (HCM) Latest News

28 Oct

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

26 Oct

Impact 4 · 8:00 PM · GlobeNewswire

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

Impact 4 · 4:30 AM · GlobeNewswire

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

25 Oct

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

Impact 4 · 3:12 AM · Simply Wall St.

What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For Shareholders

22 Oct

Impact 4 · 8:19 PM · Simply Wall St.

HUTCHMED (China) (AIM:HCM) Closes GSK Deal, Is The Stock Still 38% Undervalued?

20 Oct

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

12 Oct

Impact 4 · 11:16 PM · Simply Wall St.

How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo

28 Sep

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

27 Sep

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

24 Sep

Impact 4 · 4:59 PM · Insider Monkey

GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

23 Sep

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

3 Sep

Impact 5 · 1:02 PM · MarketBeat

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Impact 4 · 5:30 AM · Proactive Investors

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

Impact 4 · 3:27 AM · Proactive Investors

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

Impact 4 · 12:00 AM

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

30 Aug

Impact 4 · 8:00 PM

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

27 Aug

Impact 4 · 8:00 PM

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

17 Aug

Impact 4 · 10:37 AM · Proactive Investors

HUTCHMED shares rise as lung cancer drug trial hits key targets

16 Aug

Impact 4 · 8:00 PM

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

30 Jul

Impact 4 · 3:02 PM transcript

HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ...

2 Jul

Impact 4 · 4:30 AM

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

24 Jun

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

21 May

Impact 4 · 6:00 AM · GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

Impact 4 · 6:00 AM · PR Newswire

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

29 Apr

Impact 4 · 6:00 AM · GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

28 Apr

Impact 4 · 11:12 PM · MarketBeat

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference

22 Mar

Impact 4 · 8:00 PM · GlobeNewswire

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

11 Mar

Impact 4 · 9:02 PM · GuruFocus.com

HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ...

5 Mar

Impact 4 · 9:07 PM · MarketBeat

HUTCHMED H2 Earnings Call Highlights

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

HUTCHMED (China) Limited Sponsored ADR vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

HUTCHMED (China) Limited Sponsored ADR (HCM) Latest News

28 Oct

26 Oct

25 Oct

22 Oct

20 Oct

12 Oct

28 Sep

27 Sep

24 Sep

23 Sep

3 Sep

30 Aug

27 Aug

17 Aug

16 Aug

30 Jul

2 Jul

24 Jun

21 May

29 Apr

28 Apr

22 Mar

11 Mar

5 Mar

HCM metrics, ten years each

Stockrow Weekly